胰腺导管内乳头状黏液性肿瘤:2017年国际共识指南应用CT和MRI的诊断效能
回顾性纳入2009至2019年接受手术切除的175例胰腺导管内乳头状黏液性肿瘤患者,评估2017年国际共识指南高危征象与担忧特征对恶性的预测价值,并比较增强CT与MRI的诊断效能。结果显示高危征象与恶性关联最强,MRI识别壁结节优于CT,但两者鉴别良恶性的诊断准确率无显著差异(73.7% vs. 75.4%,p=0.505)。
要点
- 2017年国际共识指南中的高危征象(主胰管≥10 mm、壁结节≥5 mm、梗阻性黄疸)与恶性IPMN关联最强。
- MRI识别强化壁结节优于CT,但CT与MRI鉴别良恶性IPMN的诊断准确率无显著差异。
- MRI上壁结节<5 mm也与恶性IPMN相关(OR 5.3,p=0.009)。
关键影像表现/征象
- MRI识别强化壁结节优于CT。
- CT与MRI对高危征象的诊断准确率分别为73.7%和75.4%,两者间一致性良好至优秀。
诊断标准与关键数值
- CT和MRI上,三个高危征象(主胰管≥10 mm、壁结节≥5 mm、梗阻性黄疸)及两个担忧特征(主胰管5-9 mm、CA19-9升高)均与恶性IPMN相关(p<0.05)。
- MRI上壁结节<5 mm与恶性IPMN相关(OR 5.3,p=0.009)。
- 高危征象诊断准确率CT 73.7% vs. MRI 75.4%(p=0.505),无显著差异。
临床应用与阅片要点
- 阅片时应按2017年国际共识指南系统评估高危征象和担忧特征,其中高危征象对恶性提示意义最强。
- MRI对壁结节的显示优于CT,但两者鉴别良恶性的整体诊断效能相似,选择检查方法时可综合考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the diagnostic performance of the 2017 international consensus guidelines for intraductal papillary mucinous neoplasm (IPMN) of the pancreas and to compare the diagnostic performance and intermodality agreement between contrast-enhanced CT and MRI.
METHODS: We retrospectively evaluated patients with surgical resection of IPMN of the pancreas who underwent preoperative CT and MRI between 2009 and 2019. Two radiologists evaluated the clinical and imaging features of IPMN of pancreas according to the 2017 international consensus guideline. Univariable and multivariable analyses were performed to identify significant predictors of malignancy in IPMN. The diagnostic abilities of CT and MRI were compared, and their intermodality agreement was determined.
RESULTS: Of 175 patients (mean age, 64 years; 116 males), 88 (50.3%) had malignant IPMN. On multivariable analysis, all three high-risk stigmata (main pancreatic duct [MPD] ≥ 10 mm, mural nodule ≥ 5 mm, and obstructive jaundice) and two worrisome features (MPD 5-9 mm and elevated carbohydrate antigen 19-9) were associated with malignant IPMN on CT and MRI (p < 0.05). A mural nodule < 5 mm on MRI was also associated with malignant IPMN (OR 5.3, p = 0.009). The diagnostic accuracy of high-risk stigmata showed no difference between CT and MRI (73.7% vs. 75.4%, p = 0.505), with good to excellent intermodality agreement.
CONCLUSIONS: Current high-risk stigmata had the strongest association with malignant IPMN on CT and MRI. Although MRI is superior to CT for identifying mural nodules, diagnostic performance for differentiating malignant from benign IPMNs was similar between CT and MRI.
KEY POINTS: • The current high-risk stigmata in the 2017 International Consensus Guidelines had the strongest association with malignant IPMN on CT and MRI. • MRI is better than CT for identifying enhancing mural nodule. • Diagnostic performance for differentiating malignant from benign IPMNs was similar between CT and MRI.
引用
- Min JH, Kim YK, Kim SK, et al. Intraductal papillary mucinous neoplasm of the pancreas: diagnostic performance of the 2017 international consensus guidelines using CT and MRI. Eur Radiol. 2021. PMID: 33409798. doi:10.1007/s00330-020-07583-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。